Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study by unknown
RESEARCH ARTICLE Open Access
Predictive value of vrk 1 and 2 for rectal
adenocarcinoma response to neoadjuvant
chemoradiation therapy: a retrospective
observational cohort study
Laura del Puerto-Nevado1, Juan Pablo Marin-Arango2, Maria Jesus Fernandez-Aceñero3,4, David Arroyo-Manzano5,
Javier Martinez-Useros1, Aurea Borrero-Palacios1, Maria Rodriguez-Remirez1, Arancha Cebrian1,
Teresa Gomez del Pulgar1, Marlid Cruz-Ramos1, Cristina Carames1, Begoña Lopez-Botet2
and Jesús Garcia-Foncillas1*
Abstract
Background: Neoadjuvant chemoradiotherapy (NACRT) followed by surgical resection is the standard therapy
for locally advanced rectal cancer. However, tumor response following NACRT varies, ranging from pathologic
complete response to disease progression. We evaluated the kinases VRK1 and VRK2, which are known to
play multiple roles in cellular proliferation, cell cycle regulation, and carcinogenesis, and as such are potential
predictors of tumor response and may aid in identifying patients who could benefit from NACRT.
Methods: Sixty-seven pretreatment biopsies were examined for VRK1 and VRK2 expression using tissue
microarrays. VRK1 and VRK2 Histoscores were combined by linear addition, resulting in a new variable
designated as “composite score”, and the statistical significance of this variable was assessed by univariate
and multivariate logistic regression. The Hosmer-Lemeshow goodness-of-fit test and area under the ROC
curve (AUC) analysis were carried out to evaluate calibration and discrimination, respectively. A nomogram
was also developed.
Results: Univariate logistic regression showed that tumor size as well as composite score were statistically
significant. Both variables remained significant in the multivariate analysis, obtaining an OR for tumor size
of 0.65 (95 % CI, 0.45–0.94; p = 0.021) and composite score of 1.24 (95 % CI, 1.07–1.48; p = 0.005).
Hosmer-Lemeshow test showed an adequate model calibration (p = 0.630) and good discrimination
was also achieved, AUC 0.79 (95 % CI, 0.68–0.90).
Conclusions: This study provides novel data on the role of VRK1 and VRK2 in predicting tumor response
to NACRT, and we propose a model with high predictive ability which could have a substantial impact
on clinical management of locally advanced rectal cancer.
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Background
Neoadjuvant chemoradiation therapy (NACRT) followed
by surgical resection is widely accepted as the standard
therapeutic algorithm for locally advanced rectal cancer
[1, 2]. A wide range of tumor responses has been shown
following NACRT, ranging from pathologic complete
response to progression of the disease. The universally
accepted clinicopathological variables for assessing tumor
response after neoadjuvant treatment are tumor regres-
sion grade (TRG) and tumor downstaging [3]. The evalu-
ation of both parameters has been highly associated to
sphincter preservation following curative resection in
these patients [4, 5]. Therefore, the search for biomarkers
that can be used to predict the tumor response might
significantly impact patient selection for preoperative
chemoradiotherapy as well as modify treatment strategy
after NACRT [6, 7].
The group of vaccinia-related kinases received its name
from vaccinia virus B1R, a serine/threonine kinase present
in infecting virions which is essential for viral DNA
synthesis [8]. Given their significant degree of homology
to B1R, human vaccinia-related kinases may have similar
functions [9]. The mammalian kinase family comprises
three members: VRK1, VRK2, and the catalytically inert
VRK3 [10].
VRK1 has been reported as an early-response gene re-
quired for entry into G1 [11]. This protein is also involved
in the phosphorylation of several transcriptional factors,
including c-Jun, ATF2 [12], CREB [13], as well as p53 [14]
or histone H3 [15]. In addition to its role as a kinase,
VRK1 is also required for the assembly of 53BP1 in
response to ionizing radiation-induced DNA damage [16]
and it has recently been reported as playing an important
role in the DNA damage response (DDR) at a chromatin
level, phosphorylating H2AX histone [17].
Results found by several authors link the role played by
VRK2 with cellular response to hypoxia, with interleukin-
1 [18, 19] and with the MAPK signaling through its inter-
action with KSR1 which results in the ERK1/2 recruit-
ment to the complex, modulating the MEK/ERK pathway
[20, 21]. In addition, both kinases have been related to
the phosphorylation of BAF (barrier to autointegration
factor), a DNA binding protein that is pivotal to nuclear
envelope dynamics [22].
Beyond the in vitro data and the wide body of evidence
suggesting the involvement of this kinase family in
tumoral processes, a number of authors have found rela-
tionships between the expression of both kinases and
several human cancers. In accordance to this, it was
found that the expression of VRK1 was preferentially
expressed in the proliferation area in head and neck squa-
mous cell carcinoma patients [23], and various authors
have highlighted its potential role as a poor-outcome
biomarker in human breast carcinomas [24]. By contrast,
data related to VRK2 expression identify a subgroup of
primary high-grade astrocytomas with a better prognosis
[25], and results obtained from 136 cases of human breast
carcinoma showed that VRK2 downregulation contributes
to breast cancer phenotype [20]. Taken together, this
evidence supports the assessment of both proteins in
pretreatment biopsies and their evaluation as potential
predictors of pathological response and T downstaging by




From November 2006 to May 2013, data from 75 patients
with locally advanced (T3-4, N0, or Tany, N1-2) rectal
cancer who received NACRT followed by proctectomy at
the Fundación Jiménez Díaz Hospital (Spain) were
collected in a database. As immunohistochemical and/or
post-treatment TNM stage (T) data were missing for
eight patients, only 67 were included in the analysis.
Preoperative staging was determined by combined evalu-
ation from rectal magnetic resonance imaging (MRI),
computed tomography, trans-rectal ultrasound (TRUS),
and/or endoscopy. Pretreatment samples were taken endo-
scopically, all histologic slides were reviewed and, accor-
ding to the recommendations of the College of American
Pathologists, a two-tiered system was used to grade
tumors into two groups, i.e., low grade (greater than 50 %
gland formation) and moderate-to-high grade (less than or
equal to 50 % gland formation) [26].
Neoadjuvant therapy consisted of radiotherapy in 28
sessions during which 45 Grays (Gy) were administered
to the pelvic area and 50.4 Gy to the tumor zone, with
daily fractions of 1.8 Gy on five consecutive days per
week. Concomitant fluoropyrimidine-based chemothe-
rapy (standard regimen of 5-FU or capecitabine) was
administered. In 14 patients (19 %), flouropyrimidine-
based chemotherapy was combined with oxaliplatin. All
patients underwent surgery between 6 and 8 weeks after
completion of NACRT.
All patients gave written informed consent and sample
collection was carried out with the approval of the Insti-
tutional Scientific and Ethical Committee (CEIC-FJD)
under approval code 17/14; the evaluation for this study
was held on December 9, 2014.
Assessment of treatment response and tumor
downstaging
All the specimens obtained from rectal resection after
neoadjuvant therapy were analyzed following the standar-
dized protocol used in the Surgical Pathology Department.
According to the recommendations of the College of
American Pathologists, the criteria of Ryan were used as
follows to quantify tumor regression grade (TRG): grade 0
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(absence of tumor cells); grade 1 (fibrosis with isolated
tumor cells); grade 2 (tumor nests outgrown by fibrosis);
and grade 3 (minimal or no tumor kill). For this study, all
slides were reviewed by an experienced pathologist (MJFA)
and the results were compared with the response included
in the original report. The concordance between this new
evaluation of response and the evaluation reported by the
original pathologist who diagnosed the case was over 95 %.
T downstaging was determined by comparing pretreatment
TNM staging and restaging by pathological examination of
the surgical specimen stage.
For this study, patients with TRG 0 or 1 and/or T
downstaging were considered as responders, whereas
patients classified with regression grades 2 or 3 and no
T downstaging were judged to be non-responders.
Immunohistochemical evaluation and scoring
Formalin-fixed, paraffin-embedded (FFPE) tissue sam-
ples from 75 pretreatment biopsies obtained from rectal
cancer patients were used for tissue microarray (TMA)
construction. Representative tumor regions from biopsies
were identified by a pathologist (MJFA) on hematoxylin-
and eosin-stained tissue sections. After pathologist re-
view, TMAs were assembled from triplicate 0.6-mm
cores of FFPE biopsy tumor samples using the TMA
workstation MTA-1 (Beecher Instruments). All the immu-
nohistochemical techniques were performed in the Sur-
gical Pathology Department at Fundación Jiménez Díaz in
a Dako Autostainer. The primary antibodies were used
with the following conditions, anti-VRK1 (1:100; Sigma-
Aldrich) and anti-VRK2 (1:250; Abcam). FFPE tissue sam-
ples from healthy testis and pancreas were stained as
positive controls for VRK1 and VRK2 expression, respec-
tively (according to the Human Protein Atlas at http://
www.proteinatlas.org).
Histoscore (H-score) of VRK1 and VRK2 expression
was determined by the Quick Score method [27]. Briefly,
this method considers both the intensity and proportion
of cells stained for each case; scores of 0 to 3 indicate the
intensity (0 = no staining; 1 = light staining; 2 =moderate
staining; 3 = strong intensity), while scores 1 to 6 represent
the proportion of staining (1 = 0 to 4 %; 2 = 5 to 20 %; 3 =
21 to 40 %; 4 = 41 to 60 %; 5 = 61 to 80 %; 6 = 81 to
100 %); subsequently, by multiplying these two variables,
we calculated the H-score for VRK1 and VRK2 in each
individual case.
The linear addition of VRK1 and VRK2 H-scores
resulted in a new combined variable designated as “com-
posite score”.
All slides were evaluated in blinded fashion by two in-
vestigators (MJFA and LPN). Cases with disagreement
were reviewed using a multiheaded microscope until
agreement was achieved.
Statistical analyses
Patients characteristics were reported as frequency (and
percentage) for qualitative variables and median (Interquar-
tile Range, IQR) for quantitative ones. The relationship be-
tween H-score and clinicopathological characteristics was
assessed by the U Mann–Whitney test for qualitatives char-
acteristics and Pearson’s correlation for the quantitatives.
Table 1 Clinicopathological characteristics of the participating
patients
Variables (N = 67)
Age, years, median (IQR) 72 (63; 77)
Gender
Male 43 (64.2 %)
Female 24 (35.8 %)
ECOG performance status
0 38 (56.7 %)
≥ 1 29 (43.3 %)
Tumor invasion depth
T1 1 (1.5 %)
T2 9 (13.4 %)
T3 53 (79.1 %)
T4 4 (6 %)
Lymph node metastases
N0 13 (19.4 %)
N+ 54 (80.6 %)
Grade of differentiation (N = 60)
Low grade 17 (28.3 %)
Moderate-High grade 43 (71.7 %)
LVI (N = 63)
Yes 6 (9.5 %)
No 57 (90.4 %)
Tumor size, cm, median (IQR) 5 (4; 6)
Anal verge distance, cm, median (IQR) 8 (5; 10)
Neoadjuvant chemoradiotherapy
RDT- Flouropyrimidines 54 (80.6 %)
RDT- Flouropyrimidines - Oxaliplatin 13 (19.4 %)
T downstaging
Yes 36 (53.7 %)
No 31 (46.3 %)
Tumor Regression Grading
TRG 0 - 1 31 (46.3 %)
TRG 2 - 3 36 (53.7 %)
Responder
Yes 45 (67.2 %)
No 22 (32.8 %)
Abbreviations: ECOG Eastern Cooperative Oncology Group, RDT radiotherapy,
TRG tumor regression grading, LVI lymphovascular invasion, IQR Interquartile
Range, reported as quartile 1st and 3th, respectively
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The relationship between clinical-molecular variables and
the response status was also assessed, by a binary logistic
univariante regression, and then, a multivariate analysis was
carried out. The maximum number of covariates was
supported by the number of events observed, according to
Perduzzi et al. [28]. The multivariate model calibration was
assessed by Hosmer-Lemeshow test of goodness-of-fit and
graphically by decile groups of probability, through a cali-
bration plot. The Area Under the ROC Curve was esti-
mated to evaluate the discrimination ability of the model. A
nomogram to visualize the covariates effect to NACRT
response was developed. All statistical analyses were carried
out using R (version 3.2.1) [29–31]. A p value lower than
0.05 was considered statistically significant in all analyses.
Results
Patients and NACRT response
Patient characteristics and pathological data are listed in
Table 1. The study involved 24 females and 43 males, with
a median age (IQR) of 72 years (63; 77 years). Regarding
performance status, 38 patients (56.7 %) were classified as
ECOG 0 and the remaining (43.3 %) were classified as
ECOG ≥ 1. Median tumor size was 5.0 cm (4; 6 cm), and
the median distance from the anal verge was 8 cm (5;
10 cm). Fifty-three patients (79.1 %), were staged as T3,
and 54 patients (80.6 %) were endorsed as N+. Forty-three
tumors (71.7 %) were moderate-high graded, and 57
patients (90.4 %) did not show lymphovascular invasion.
Fifty-four patients (80.6 %) enrolled in the study received
NACRT consisting of radiotherapy (RDT) + fluoropyrimi-
dine, and 13 received RDT + fluoropyrimidine combined
with oxaliplatin (19.4 %). After neoadjuvant chemoradio-
therapy and surgery, T downstaging was detected in 36
patients (53.7 %), and 31 (46.3 %) exhibited a response of
grade 0 or 1 according to the scheme of Ryan (complete
response as well as patients who had only isolated tumor
cells after neoadjuvant treatment). The combined out-
come resulted in 45 responders (67.2 %) and 22 non-
responders (32.8 %).
Relationship of clinical and molecular variables with
NACRT response
VRK1 and VRK2 expression were assessed by immunohis-
tochemistry. Stained cases of responder and non responder
patients with anti-VRK1 and anti-VRK2 antibodies are
represented in Fig. 1. Concerning the expression pattern,
VRK1 was detected in the nucleus, while VRK2 was
observed mainly in the cytoplasm of tumor cells. After
expression was assessed, H-scores for each biomarker were
calculated, revealing a median value (IQR) of 4 (2; 6) for
VRK1 and 0 (0; 6) for VRK2. H-score values for both
biomarkers are represented in histograms (Fig. 1).
In univariate analysis of NACRT response, the vari-










































Fig. 1 Immunohistochemical expression in rectal cancer biopsies before neoadjuvant therapy in responder and non responder patients. Pictures
show high expression of VRK1 and VRK2 in a responder patient (upper image) and low expression of both proteins in a non responder patient
(lower image). Images were taken with a magnification of x200. 1.2. Histograms represent H-score distribution obtained from staining of VRK1
and VRK2 for the whole series of locally advanced rectal cancer patients
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node metastases, lymphovascular invasion, distance from
the anal verge, grade of differentiation, as well as neoad-
juvant treatment were not significant. The only clinical
variable that showed association to response was the
tumor size (OR, 0.65; 95 % CI, 0.46–0.90; p = 0.011).
Regarding molecular markers, univariate analysis showed
a significant association for both VRK1 (OR, 1.20; 95 %
CI, 1.01–1.43, p = 0.033) and VRK2 (OR, 1.23; 95 % CI,
1.03–1.50; p = 0.023) with response to NACRT.
The analysis of the addition of VRK1 and VRK2 H-
scores, resulted in a new combined composite score
(OR, 1.24; 95 % CI, 1.07–1.44; p = 0.004), that were not
statistically associated or correlated with clinicopatho-
logical characteristics, as is shown in Additional file 1:
Table S1, and which improved the model likelihood with
respect to VRK1 (LRTest, p = 0.009) and VRK2 H-scores
(LRTest, p = 0.016) separately.
Multivariate regression analysis of tumor size and com-
posite score, showed that were not interaction or confu-
sion between them, and both variables together remained
statistically significant to predict NACRT response (OR,
0.65, 95 % CI, 0.45–0.94; p = 0.021 for tumor size and OR,
1.24, 95 % CI, 1.07–1.48; p = 0.005 for composite score) as
is shown in Table 2.
Predictive value of tumor size and composite score
The calibration of the multivariate model was assessed by
Hosmer-Lemeshow test of goodness-of-fit, that evaluates
differences between estimated and observed probability,
obtaining a p-value of 0.630, Fig. 2 contains the plot of
estimated versus observed probability.
The discrimination of logistic model was assessed by
ROC curve, obtaining the AUC of 0.79 (95 % CI, 0.68–
0.90), greater than AUC values obtained by tumor size
(AUC, 0.68) or composite score (AUC, 0.73) separately
(Fig. 3.).
A nomogram was developed to assist visually the contri-
bution of each variable to the probability of NACRT
response. The nomogram score value was the combi-
nation of the specific value of tumor size and composite
score independent values; together, these accurately quan-
tified the probability of response to treatment for each
particular patient (Fig. 4).
Discussion
Neoadjuvant concurrent chemoradiotherapy is widely
used for rectal cancer to improve local tumor control
[1, 2]. However, the varied response of individual tumors
has led us to search for useful biomarkers to predict
response to neoadjuvant treatment. In patients receiving
this therapy, TRG and tumor downstaging have become
universally accepted for assessing tumor response [3].
Based on previous reports showing an association between
Table 2 Uni- and multivariate analysis in locally advanced rectal
adenocarcinoma patients
Univariate Multivariate




















































VRK1 HSCORE (continuous) 1.20
(1.01–1.43)
0.033










Abbreviations: OR odds ratio, CI confidence interval, LVI lymphovascular
invasion, ECOG Eastern cooperative oncology; group, RDT radiotherapy
β0 = 1.57/βtumor size = -0.44/βComposite score = 0.22
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VRK1 and VRK2 and their role in several tumor pro-
cesses, we evaluated the levels of both proteins in pretreat-
ment biopsies with the aim of assessing their potential as
predictors of pathological response and T downstaging by
neoadjuvant chemoradiation. Our analysis showed that
higher scores of both biomarkers were associated with
patient designation as responders. Furthermore, the linear
addition of VRK1 and VRK2 H-scores resulted in a new
composite score that not only remained statistically
significant, but also showed an enhanced OR and closer
confidence intervals due to the increased precision of
this method of estimation. Together with tumor size, this
Figure. 2 Calibration plot of the estimated probability versus the observed probability
Fig. 3 Receiver operating characteristics (ROC) curve derived from tumor size, composite score and for the model resulting from the
multivariate analysis
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composite score remained statistically significant in multi-
variate analysis, supporting its use as a useful model and
featuring an optimal predictive value never reported before.
The impact of the VRK1 and VRK2 kinases in rectal
cancer is a novel contribution, providing further insight
on the potential role for these kinases in cancer and also
representing a new tool for the prediction of response to
neoadjuvant treatment in patients with locally advanced
rectal cancer. With regard to previous reports, the VRK2
results obtained from our series were consistent with
previous data [25], thereby supporting the role of VRK2
as a good prognostic biomarker. Surprisingly, the results
related with VRK1 expression in pretreatment biopsies
showed that higher H-score values were associated with
better NACRT response, indicating its good prognostic
utility. These data could be controversial due to previous
results that showed that high VRK1 expression was
associated with an ability to confer resistance to DNA-
damaging agents in human breast cancer [24]; however,
recent results suggest a potentially contradictory role of
VRK1 in the DDR to ionizing radiation [17], through its
ability to phosphorylate histone H2AX at Ser 139, which
could be directly associated with DNA ladder formation
in apoptosis [32]. These conflicting effects have also
been reported by other authors who have found oppo-
sing functions of certain proteins involved in tumori-
genesis, such as the phosphorylation of JNK and its
proliferative and antiproliferative function depending on
cell type and its crosstalk with other proteins [33], the
involvement of the transcription factor Krüppel-like
factor 4 (KLF4) in tumorigenesis as a tissue-specific
tumor suppressor or oncogene [34], or the association of
pFAK-Y397 both with distant and lymph node metastases
as well as improved overall survival in ovarian cancer
patients [35].
Given the great benefit of NACRT response predictors
for clinical practice and for rectal cancer patients, this
question has become widely studied, and several authors
have reported many molecular biomarkers for prediction
of pathological response or tumor downstaging, such as
CD44 and proliferating cell nuclear antigen mRNA
levels [36]; the gene signature composed of LRRIQ3,
FRMD3, SAMD5, and TMC7 [37]; GHRH-R and Hsp90
proteins [38]; Topo I [39]; and beclin 1 [40], survivin
[41], among others.
The main limitation of our study is its sample size. We
are well aware that the number of patients enrolled is
scarce, though we stress that patient recruitment has
been carried out by a single institution, thus ensuring
homogeneity of patient management and therefore, in
the results obtained. In light of this limitation, our
findings require further validation in additional clinical
series to confirm the potential impact of these biomarkers,
not only in terms of tumor response, but also in outcome
prediction.
Conclusion
This manuscript highlights novel data on the role of VRK1
and VRK2 in predicting tumor response to neoadjuvant
chemoradiotherapy. We additionally propose a promising
model that also concerns tumor size and provides high
prediction ability. These findings could have a substantial
impact on clinical management of locally advanced rectal
cancer.
Additional file
Additional file 1: Table S1. Relationship between clinicopathological
characteristics and biomarkers. (DOCX 21 kb)
Fig 4 Nomogram predicting tumor response before NACRT based on the statistical model obtained in the multivariate analysis
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